IN8BIO INC. - COMMON

IN8bio to Present at July Investor and Scientific Conferences

30 Jun 2022 16:15:00 By Nasdaq GlobeNewswire

IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences

08 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

06 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

17 May 2022 07:00:02 By Nasdaq GlobeNewswire

IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 May 2022 08:00:02 By Nasdaq GlobeNewswire

IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting

05 May 2022 08:00:02 By Nasdaq GlobeNewswire

IN8bio to Present at May Investor and Scientific Conferences

04 May 2022 08:00:01 By Nasdaq GlobeNewswire

IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments

13 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

IN8bio to Present at April Investor and Scientific Conferences

05 Apr 2022 16:15:00 By Nasdaq GlobeNewswire

IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

28 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

17 Mar 2022 16:15:00 By Nasdaq GlobeNewswire

IN8bio to present at March Investor and Scientific Conferences

04 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit

10 Feb 2022 17:36:28 By Nasdaq GlobeNewswire

IN8bio to Present at Upcoming January Investor Conferences

10 Jan 2022 07:00:04 By Nasdaq GlobeNewswire

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

06 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

16 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

09 Dec 2021 16:30:00 By Nasdaq GlobeNewswire

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer

16 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors

11 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

10 Nov 2021 16:15:00 By Nasdaq GlobeNewswire